Amarin Announces Additional Effects of Vascepa(R) on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the

Amarin Announces Additional Effects of Vascepa(R) on Lipoprotein Particle
Concentration From the ANCHOR Study Presented at the National Lipid
Association 2013 Annual Scientific Sessions

BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, today presented additional data on Vascepa® (icosapent ethyl) and its
effect on lipoprotein particle concentration from the Phase 3 ANCHOR study at
the National Lipid Association (NLA) 2013 Annual Scientific Session in Las
Vegas, Nevada.

The data presentation titled, "Effects of Icosapent Ethyl on Lipoprotein
Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated
Patients with Persistent High Triglycerides (the ANCHOR Study)", reported that
Vascepa 4 g/day, when added to optimized statin therapy for 12 weeks,
significantly reduced median particle concentrations of total very-low-density
lipoprotein (VLDL) by 12.2%, total low-density lipoprotein (LDL) by 7.7%, and
small LDL particles by 13.5% across the 12 week treatment period, compared
with placebo.

The ANCHOR study, authored by Christie M. Ballantyne, M.D. and colleagues,
investigated Vascepa as a treatment for high triglycerides (≥200 and
<500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid
disorders) on optimized background statin therapy who were at LDL-C
(low-density lipoprotein cholesterol) goal, and who were also at high risk of
cardiovascular disease. The original results, which were presented at the
American Heart Association in 2011, highlighted that Vascepa 4 g/day
demonstrated a significant median reduction in triglyceride levels, the
primary endpoint, of 21.5%, as well as a significant median reduction in
low-density lipoprotein cholesterol (LDL-C) of 6.2%, compared to the group of
patients on optimized statin therapy and placebo.

Amarin also presented, or provided financial support for, research surrounding
three additional topics at this year's NLA meeting, including:

  *pharmacokinetic data showing the lack of drug-drug interaction when
    Vascepa was administered with atorvastatin, a commonly prescribed
    cholesterol lowering medication
  *pharmacokinetic data showing the lack of drug-drug interaction when
    Vascepa was administered with warfarin, a commonly prescribed
    anticoagulant medication
  *eicosapentaenoic acid (EPA) and its potential inhibition of the formation
    of membrane cholesterol crystalline domains

About Vascepa® (icosapent ethyl) capsules

Vascepa®(icosapent ethyl) capsules, known in scientific literature as AMR101,
is a patented, pure-EPAomega-3 prescription product in a 1 gram capsule.

Indications and Usage

  *Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce
    triglyceride (TG) levels in adult patients with severe (≥500 mg/dL)
    hypertriglyceridemia.
  *The effect of Vascepa on the risk for pancreatitis and cardiovascular
    mortality and morbidity in patients with severe hypertriglyceridemia has
    not been determined.

Important Safety Information for Vascepa

  *Vascepa is contraindicated in patients with known hypersensitivity (e.g.,
    anaphylactic reaction) to Vascepa or any of its components and should be
    used with caution in patients with known hypersensitivity to fish and/or
    shellfish.
  *The most common reported adverse reaction (incidence >2% and greater than
    placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND ATWWW.VASCEPA.COM

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Forward-looking statements

This press release contains forward-looking statements, including statements
about the effects of Vascepa, as shown in clinical trials, to be accepted by
regulatory agencies and, if approved, reflected in clinical results and the
likelihood of regulatory submissions and approvals. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those described or projected herein include uncertainties
associated generally with research and development, clinical trials and
related regulatory submissions and approvals. A further list and description
of these risks, uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities and Exchange
Commission, including its most recent Quarterly Report on Form 10-Q. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Vascepa has been approved for use by the FDA as an adjunct to diet to reduce
triglyceride levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.Vascepa is under various stages of development for
potential use in other indications that have not been approved by the
FDA.Nothing in this press release should be construed as marketing the use of
Vascepa in any indication that has not been approved by the FDA.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo